Photo from Aaron Goodman/X
Feb 1, 2024, 11:52
Aaron Goodman: Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
Aaron Goodman shared a post on X/Twitter:
“Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy | NEJM
In relapsed/refractory aggressive lymphomas,leukemias CART has a place.
However, we should pause and figure this out before we give CART first line myeloma and smoldering.”
Source: Aaron Goodman/X
Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14